ARCT · Arcturus Therapeutics Holdings Inc.
$8.23
+0.37 (+4.71%)
At close · Aug 14
Market Cap
$233.92M
Shares
28.42M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.23
Open$7.86
Day$7.71–8.48
52W close$5.53–23.16
Avg vol 30d542K
Short int7.2M · 25.4% float · 16.5d
Short vol61%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+12%
above
Price vs 50-day avg
+21%
above
RSI (14)
71
overbought
MACD trend
Positive
52-week position
15%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+36%
trailing
6-month return
+7%
trailing
YTD return
+34%
this year
Relative strength
−6%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
25.36% of float · ▲ +2.9% MoM · 16.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
133 holders — mid 3-yr range
Squeeze score
85
high risk · 0–100
Fundamentals
Revenue growth
−46%
Y/Y
EPS growth
+20%
Y/Y
Free cash flow
$-74.5M
Balance sheet
$129.6M
net cash
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−76%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+12%
Bullish
Price vs 50-day avg
+21%
Bullish
RSI (14)
71
Bearish
MACD trend
Positive
Bullish
52-week position
15%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
25.36% of float · ▲ +2.9% MoM · 16.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
133 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6
Now $8 · 15%
Range high $23
vs 200-day avg +12%
vs 50-day avg +21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARCT
this stock
Arcturus Therapeutics Holdings Inc.
|
$233.92M | +34.3% | -46.1% | — | 25.4% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARCT | +11.1% | +36.0% | +7.3% | +42.9% | +34.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +10.7% | +31.6% | -6.5% | +39.0% | +20.4% |
Key facts
CIK
1768224
CUSIP
03969T109
13F (30d)
129 filings
128 filers
Visit website
Investor relations